

Resource Summary Report

Generated by [NIF](#) on Sep 12, 2026

NCI-H2110

RRID:CVCL_1530

Type: Cell Line

Proper Citation

RRID:CVCL_1530

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1530

Proper Citation: RRID:CVCL_1530

Description: Cell line NCI-H2110 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Sex unspecified

Disease: Lung non-small cell carcinoma

Defining Citation: [PMID:8806092](#), [PMID:22460905](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:26589293](#), [PMID:27397505](#), [PMID:28196595](#), [PMID:29681454](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:31803961](#), [PMID:31978347](#), [PMID:35839778](#)

Comments: Population: African American., Part of: MD Anderson Cell Lines Project., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: NCI-H2110

Synonyms: H2110, H-2110, NCIH2110

Cross References: BTO:BTO_0006021, CLO:CLO_0008054, EFO:EFO_0006673, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ATCC:CRL-5924, BioGRID_ORCS_Cell_line:532, BioSample:SAMN03473198, BioSample:SAMN10987977, cancercellines:CVCL_1530, Cell_Model_Passport:SIDM00703, CLS:305838, Cosmic:1146901, Cosmic-CLP:1298351, DepMap:ACH-000929, EGA:EGAS00001000610, EGA:EGAS00001000978, GDSC:1298351, GEO:GSM434270, GEO:GSM887405, GEO:GSM888484,

GEO:GSM1670216, IGRhCellID:H2110GEO, LiGeA:CCLE_265, LINCS_LDP:LCL-1616, PharmacDB:NCIH2110_1069_2019, PRIDE:PXD030304, Progenetix:CVCL_1530, Wikidata:Q54907926

ID: CVCL_1530

Record Creation Time: 20220427T220839+0000

Record Last Update: 20260905T181243+0000

Ratings and Alerts

No rating or validation information has been found for NCI-H2110.

No alerts have been found for NCI-H2110.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 8 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Takano K, et al. (2026) DS-3939a: A TA-MUC1-Directed Antibody-Drug Conjugate with Broad Antitumor Activity. Molecular cancer therapeutics, 25(1), 7.

Mozzarelli AM, et al. (2025) RIT1 Drives Oncogenic Transformation and Is an Actionable Target in Lung Adenocarcinoma. Cancer research, 85(17), 3196.

Jeong J, et al. (2025) NSD2 inhibitors rewire chromatin to treat lung and pancreatic cancers. Nature.

Graham K, et al. (2024) Discovery of YAP1/TAZ pathway inhibitors through phenotypic screening with potent anti-tumor activity via blockade of Rho-GTPase signaling. Cell chemical biology, 31(7), 1247.

Sadeghi M, et al. (2024) Biased signaling by mutant EGFR underlies dependence on PKC ? in lung adenocarcinoma. Cell reports, 43(12), 115026.

Weinstein HNW, et al. (2024) RPL22 is a tumor suppressor in MSI-high cancers and a splicing regulator of MDM4. Cell reports, 43(8), 114622.

Riley AK, et al. (2024) The deubiquitinase USP9X regulates RIT1 protein abundance and oncogenic phenotypes. iScience, 27(8), 110499.

Köferle A, et al. (2022) Interrogation of cancer gene dependencies reveals paralog interactions of autosome and sex chromosome-encoded genes. Cell reports, 39(2), 110636.